| scholarly article | Q13442814 |
| P50 | author | Steven Rosenberg | Q2347448 |
| P2093 | author name string | Donohue JH | |
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 2203-2208 | |
| P577 | publication date | 1983-05-01 | |
| P1433 | published in | Journal of Immunology | Q3521441 |
| P1476 | title | The fate of interleukin-2 after in vivo administration | |
| P478 | volume | 130 |
| Q68059367 | 1,3-Bis(2-chloroethyl)-1-nitrosourea (BCNU)/interleukin-2 chemoimmunotherapy of murine L1210 leukemia |
| Q36467473 | A phase I clinical trial of recombinant interleukin 2 following high dose chemo-radiotherapy for haematological malignancy: applicability to the elimination of minimal residual disease |
| Q92459952 | A strategy for the selection of monovalent antibodies that span protein dimer interfaces |
| Q70229777 | Antitumor and therapeutic effects of spleen cells from tumor-bearing mice cultured with T cell growth factor and soluble tumor extract |
| Q41912528 | Antitumor effects of a new interleukin-2 slow delivery system on methylcholanthrene-induced fibrosarcoma in mice |
| Q68793063 | Augmentation of NK activity and/or macrophage-mediated cytotoxicity in the liver by biological response modifiers including human recombinant interleukin 2 |
| Q63965639 | Augmentation of the therapeutic efficacy of adoptive tumor immunotherapy by in vivo administration of slowly released recombinant interleukin 2 |
| Q33811204 | Challenges and developing solutions for increasing the benefits of IL-2 treatment in tumor therapy |
| Q54421785 | Characteristics of murine non-specific killer cells induced in vivo by recombinant human interleukin-2. |
| Q34604057 | Chemical modification of recombinant interleukin 2 by polyethylene glycol increases its potency in the murine Meth A sarcoma model |
| Q72092554 | Clinical and immunological effect of intravesical interleukin-2 on superficial bladder cancer |
| Q41915301 | Clinical responses to adoptive T-cell transfer can be modeled in an autologous immune-humanized mouse model |
| Q35600299 | Co-expression of tumor antigen and interleukin-2 from an adenoviral vector augments the efficiency of therapeutic tumor vaccination |
| Q55369043 | Combination treatment with irritant and recombinant interleukin 2 in the peritoneal cavity for evoking effective anti-tumor activity: generation of lymphokine-activated killer cells and tumor-specific killer cells. |
| Q70228209 | Cytokines and the chronic inflammation of rheumatic disease. II. The presence of interleukin-2 in synovial fluids |
| Q44021006 | Effect of T cell modulation on the translocation of bacteria from the gut and mesenteric lymph node |
| Q36962448 | Effect of adoptive transfer of cloned Actinobacillus actinomycetemcomitans-specific T helper cells on periodontal disease |
| Q45859142 | Effect of human, recombinant interleukin 2 on Punta Toro virus infections in C57BL/6 mice |
| Q69873270 | Effector mechanisms of syngeneic anti-tumour responses in mice. II. Cytotoxic T lymphocytes mediate neutralization and rejection of radiation-induced leukaemia RL male 1 in the nude mouse system |
| Q41458688 | Effects of route and formulation on clinical pharmacokinetics of interleukin-2. |
| Q36466665 | Efficacy of chemoimmunotherapy with cyclophosphamide, interleukin-2 and lymphokine activated killer cells in an intraperitoneal murine tumour model |
| Q38837036 | Emerging nanotechnologies for cancer immunotherapy |
| Q54963796 | Enhancement of therapeutic effect of interleukin-2 on spontaneous pulmonary metastases of Lewis lung carcinoma by killer helper factor associated with increased induction of killer activity. |
| Q64102482 | Focused Ultrasound Improves NK-92MI Cells Infiltration Into Tumors |
| Q72374056 | Generation of tumor-specific cytotoxic T lymphocytes in vivo by combined treatment with inactivated tumor cells and recombinant interleukin-2 |
| Q47108872 | IL-2 imprints human naive B cell fate towards plasma cell through ERK/ELK1-mediated BACH2 repression. |
| Q27304738 | IL-2 sensitivity and exogenous IL-2 concentration gradient tune the productive contact duration of CD8(+) T cell-APC: a multiscale modeling study |
| Q33719745 | IL-2/anti-IL-2 antibody complexes show strong biological activity by avoiding interaction with IL-2 receptor alpha subunit CD25 |
| Q30252348 | IL233, A Novel IL-2 and IL-33 Hybrid Cytokine, Ameliorates Renal injury |
| Q36350373 | Immunization with antigen and interleukin 2 in vivo overcomes Ir gene low responsiveness |
| Q67975323 | Immunosuppression follows systemic T lymphocyte activation in the burn patient |
| Q24548127 | Immunotherapy for cancer: the use of lymphokine activated killer (LAK) cells |
| Q42038599 | Immunotherapy of hepatocellular carcinoma with autologous lymphokine-activated killer cells and/or recombinant interleukin-2. |
| Q39740458 | Improved pharmacokinetics and reduced antibody reactivity of lysostaphin conjugated to polyethylene glycol |
| Q68094892 | Improved therapeutic effects of interleukin 2 after the accumulation of lymphokine-activated killer cells in tumor tissue of mice previously treated with cyclophosphamide |
| Q50919805 | In vivo Effects of Interleukin 2 on Lymphocyte Subpopulations in a Patient with a Combined Immunodeficiency |
| Q40176700 | In vivo and in vitro administration of interleukin 2-containing preparation reverses T-cell unresponsiveness in Mycobacterium bovis BCG-infected mice. |
| Q68802117 | In vivo augmentation of the cytotoxicity of spleen lymphocytes against syngeneic B-16 melanoma cells and the suppression of the artificial metastases in C57BL/6 mice by subcutaneous multiple injections of high dose human recombinant interleukin-2 (r |
| Q68091272 | In vivo generation of lymphokine activated killer cell activity by ABPP and interleukin-2 and their antitumor effects against immunogenic and nonimmunogenic tumors in murine tumor models |
| Q37048794 | Interleukin 2 enhances specific and nonspecific immune responses in experimental Chagas' disease |
| Q36028807 | Interleukin-2 activity can be fine tuned with engineered receptor signaling clamps. |
| Q69865226 | Interleukin-2 in vivo: production of and response to interleukin-2 in lymphoid organs undergoing a primary immune response to heterologous erythrocytes |
| Q34306890 | Interleukin-2. A review of its pharmacological properties and therapeutic use in patients with cancer |
| Q36869456 | Interleukins. Clinical pharmacokinetics and practical implications |
| Q40397046 | Interleukins. Clinical pharmacology and therapeutic use. |
| Q45888906 | Intralymphatic interleukin-2 treatment of a hemophiliac AIDS patient with defective interleukin-2 production |
| Q27027097 | Intravenous ascorbic acid as an adjuvant to interleukin-2 immunotherapy |
| Q37906267 | Local and regional immunotherapy of cancer with interleukin 2. |
| Q34525728 | Long-term engraftment of human natural T regulatory cells in NOD/SCID IL2rγc(null) mice by expression of human IL-2. |
| Q67902970 | Malignant melanoma and renal cell carcinoma: Immunological and haematological effects of recombinant human interleukin-2 |
| Q42607562 | Modulation of CD4+ T Lymphocyte Lineage Outcomes with Targeted, Nanoparticle-Mediated Cytokine Delivery |
| Q67984891 | Modulation of Mycobacterium avium growth in vivo by cytokines: involvement of tumour necrosis factor in resistance to atypical mycobacteria |
| Q55248103 | Multiple Sclerosis and the LIF/IL-6 Axis: Use of Nanotechnology to Harness the Tolerogenic and Reparative Properties of LIF. |
| Q36229611 | Naive CD8+ T cells differentiate into protective memory-like cells after IL-2 anti IL-2 complex treatment in vivo |
| Q47203993 | Nanoparticle anchoring targets immune agonists to tumors enabling anti-cancer immunity without systemic toxicity |
| Q26773135 | Natural Killer Cell-Based Therapies Targeting Cancer: Possible Strategies to Gain and Sustain Anti-Tumor Activity |
| Q40336066 | Noninvasive monitoring of cancer therapy induced activated T cells using [18F]FB-IL-2 PET imaging |
| Q64959685 | Opposite effects of interleukin-2 on normal and transfusion-suppressed healing of experimental intestinal anastomoses. |
| Q43791364 | Oxidation of recombinant human interleukin-2 by potassium peroxodisulfate |
| Q41017625 | Participation of tumor necrosis factor in the mediation of gram negative bacterial lipopolysaccharide-induced injury in rabbits |
| Q42646895 | Pharmacokinetic modelling of N-(4-[(18)F]fluorobenzoyl)interleukin-2 binding to activated lymphocytes in an xenograft model of inflammation |
| Q37017209 | Prophylactic administration of interleukin-2 protects mice from lethal challenge with gram-negative bacteria. |
| Q42225944 | Quantitative absorption of interleukin-2 by peripheral blood and synovial fluid lymphocytes from patients with rheumatoid arthritis |
| Q36350050 | Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2. |
| Q34651528 | Regulatory T cells control NK cells in an insulitic lesion by depriving them of IL-2. |
| Q45163749 | Rescue of Tolerant CD8+ T Cells during Cancer Immunotherapy with IL2:Antibody Complexes |
| Q35212373 | Soluble IL-2Rα facilitates IL-2-mediated immune responses and predicts reduced survival in follicular B-cell non-Hodgkin lymphoma |
| Q34298337 | Superantigens subvert the neutrophil response to promote abscess formation and enhance Staphylococcus aureus survival in vivo |
| Q68177118 | Sustained delivery of interleukin-2 from a poloxamer 407 gel matrix following intraperitoneal injection in mice |
| Q69738719 | Synergistic induction of lymphokine (IL-2)-activated killer activity by IL-2 and the polysaccharide lentinan, and therapy of spontaneous pulmonary metastases |
| Q36370053 | Synthekines are surrogate cytokine and growth factor agonists that compel signaling through non-natural receptor dimers. |
| Q99613478 | TRI microparticles prevent inflammatory arthritis in a collagen-induced arthritis model |
| Q40949460 | Targeted Reconstitution of Cytokine Activity upon Antigen Binding using Split Cytokine Antibody Fusion Proteins |
| Q41936386 | Tethering IL2 to its receptor IL2Rβ enhances anti-tumor activity and expansion of natural killer NK92 cells |
| Q68822512 | The anti-tumour efficacy of human recombinant interleukin 2. Correlation between sensitivity of tumours to the cytolytic effect of LAK cells in vitro and their susceptibility to interleukin 2 immunotherapy in vivo |
| Q70493957 | The in vivo functions and properties of persisting cell-stimulating factor |
| Q34255232 | The role of interleukin-2 during homeostasis and activation of the immune system |
| Q68821262 | The toxicity of recombinant human interleukin-2 in rats following intravenous infusion |
| Q71007072 | Therapeutic use of interleukins: experimental results |
| Q69024451 | Transforming growth factor-beta inhibits the in vitro generation of lymphokine-activated killer cells and cytotoxic T cells |
| Q69333914 | Treatment of hepatocellular carcinoma utilizing lymphokine-activated killer cells and interleukin-2 |
| Q36421963 | Treatment of metastatic renal cell carcinoma with subcutaneous interleukin 2: evidence for non-renal clearance of cytokines. |
| Q37024825 | Treatment of mice with human recombinant interleukin-2 augments resistance to the facultative intracellular pathogen Listeria monocytogenes. |
| Q69866226 | Tumour inhibitory effects of TCGF/IL-2/-containing preparations |
Search more.